Published in Gene Therapy Weekly, October 8th, 2009
Prof. Sander van Deventer will step down as interim-CEO of AMT. He will continue to contribute to AMT as Scientific Advisor.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.